| The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients. | |
| | |
MedLine Citation:
|
PMID: 20379853 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
We investigated the factors influencing triglycerides (TG) reduction during ezetimibe, alone or combined with orlistat, administration. Eighty-six obese hypercholesterolemic subjects were prescribed a low-fat diet and were randomized to ezetimibe (E group), orlistat (O group), or both (OE group) for 6 months. Plasma TG and apolipoprotein (apo) C-III reduction was significantly greater in the combination group compared with monotherapy. Multivariate analysis showed that in E group apoC-III reduction and baseline TG levels were independently positively correlated, whereas baseline apoC-II levels were negatively correlated, with TG lowering. In OE group apoC-III reduction was the only independent contributor to TG reduction. |
| | |
Authors:
|
E S Nakou; T D Filippatos; A P Agouridis; C Kostara; E T Bairaktari; M S Elisaf |
Related Documents
:
|
8436003 - Effect on lipid metabolism of a biphasic desogestrel-containing oral contraceptive: div... 19041223 - Amino acid supplementation decreases plasma and liver triacylglycerols in elderly. 17636283 - Diet modification to reduce phosphorus surpluses: a mass balance approach. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial Date: 2010-04-09 |
Journal Detail:
|
Title: Lipids Volume: 45 ISSN: 1558-9307 ISO Abbreviation: Lipids Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-05-06 Completed Date: 2010-09-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0060450 Medline TA: Lipids Country: Germany |
Other Details:
|
Languages: eng Pagination: 445-50 Citation Subset: IM |
Affiliation:
|
Department of Internal Medicine, School of Medicine, University of Ioannina, 45 110 Ioannina, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Obesity Agents
/
pharmacology* Anticholesteremic Agents / pharmacology Apolipoprotein C-II / metabolism Apolipoprotein C-III / metabolism Azetidines / pharmacology* Diet, Fat-Restricted Drug Therapy, Combination Female Humans Lactones / pharmacology* Male Middle Aged Obesity / diet therapy, drug therapy* Triglycerides / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Obesity Agents; 0/Anticholesteremic Agents; 0/Apolipoprotein C-II; 0/Apolipoprotein C-III; 0/Azetidines; 0/Lactones; 0/Triglycerides; 163222-33-1/ezetimibe; 96829-58-2/orlistat |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Modelling the Transmission Dynamics and Control of the Novel 2009 Swine Influenza (H1N1) Pandemic.
Next Document: The Influence of Condition on Permeation of Ca(II) Ions from Solutions of Selected Calcium's Salts T...